Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

Running, not enrolling · Phase 2

Conditions studied: Hypoplastic Left Heart Syndrome

In brief

Researchers want to better understand what happens to the heart when the stem cells are injected directly into the muscle of the right side of the heart during the Stage II palliative surgery for single ventricle patients with hypoplastic left heart syndrome (HLHS) or HLHS variant. Researchers want to see if there are changes in the heart's structure/function following this stem cell-based therapy and compared to children that have not had cell-based therapy.

Key facts

Study ID

NCT03779711

Run by

Timothy J Nelson, MD, PhD

People needed

95

Starts

2019-06-06

Expected to finish

2026-02-01

Last updated by the study team

2025-07-08

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HLHS or HLHS variant with single right ventricular dependent CHD having undergone Stage I surgical repair and undergoing Stage II surgical repair.
• Less than 13 months of age at time of Stage II surgical repair
• Previous participation in the UCB collection protocol with autologous UCB-MNC product that is acceptable for use (treatment arm only)

You may not qualify if…

• History of DMSO reaction (treatment arm only).
• Parent(s) and/or legal guardian(s) unwilling to have their child participate or unwilling to follow the study procedures.
• Severe chronic diseases at the discretion of the treating physician.
• Extensive extra-cardiac syndromic features.
• Known history of cancer.
• Any of the following complications of his/her congenital heart disease:
• Any condition requiring urgent, or unplanned interventional procedure within 15 days prior to Stage II surgical repair, unless complete and full cardiac recovery is documented by site investigator
• Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure)
• Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome, not directly related to the stem cell product or its injection procedure, during or after Stage II surgical repair.

Where it is running

• Children's of Alabama — Birmingham, Alabama, United States
• Children's Hospital of Los Angeles — Los Angeles, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• Ocshner Medical Center — New Orleans, Louisiana, United States
• Children's Hospitals of Minnesota — Minneapolis, Minnesota, United States
• Cincinnati Children's Hospital and Medical Center — Cincinnati, Ohio, United States
• Oklahoma University Medical Center — Oklahoma City, Oklahoma, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.